On July 3, GLH, Sanofi announced that the EU regulatory agency approved its drug Dupixent for adults with chronic obstructive pulmonary disease in Europe. This decision makes Dupixent the first targeted therapy for about 220,000 adult patients with chronic obstructive pulmonary disease in the EU. Sanofi said the US Food and Drug Administration is also reviewing the drug and may make a decision by September 27; China's regulatory agency is also considering the drug.
赛诺菲Dupixent在欧盟获批用于治疗慢性阻塞性肺病
Sanofi's Dupixent has been approved for the treatment of chronic obstructive pulmonary disease in the European Union.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.